摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-溴-2-甲基-2H-吲唑 | 590417-95-1

中文名称
6-溴-2-甲基-2H-吲唑
中文别名
2-甲基-6-溴-2H-吲唑;6-溴-2-甲基吲唑
英文名称
6-bromo-2-methyl-2H-indazole
英文别名
6-bromo-2-methylindazole
6-溴-2-甲基-2H-吲唑化学式
CAS
590417-95-1
化学式
C8H7BrN2
mdl
——
分子量
211.061
InChiKey
BVYFYDANLZQCPV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    322.7±15.0 °C(Predicted)
  • 密度:
    1.60±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    17.8
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933990090
  • 危险标志:
    GHS07
  • 危险性描述:
    H315,H319,H335
  • 危险性防范说明:
    P305 + P351 + P338
  • 储存条件:
    室温

SDS

SDS:48ee09ef79a65422150bf75a6abfae28
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 6-Bromo-2-methyl-2H-indazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-2-methyl-2H-indazole
CAS number: 590417-95-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7BrN2
Molecular weight: 211.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-溴-2-甲基-2H-吲唑 在 sodium hydride 、 potassium carbonate 作用下, 以 1,4-二氧六环N,N-二甲基甲酰胺 、 mineral oil 为溶剂, 反应 4.5h, 生成 C25H20FN3O2
    参考文献:
    名称:
    研究双吲哚抑制剂作为HIV-1糖蛋白41融合抑制剂的分子特性。
    摘要:
    在以前的工作中,我们描述了靶向6到6-6'-双吲哚化合物作为HIV-1融合有效抑制剂的病毒糖蛋白41 N七重复序列区域上的疏水口袋。具有亚微摩尔IC50的两种有前途的化合物包含一个苯甲酸基团和一个连接在两个吲哚氮原子上的苯甲酸酯基。在这里,我们进行了详尽的结构-活性关系(SAR)研究,评估了每个环系统和各种取代基对化合物效能的贡献。改变疏水性,极性和电荷以产生35种新化合物,这些化合物在结合,细胞-细胞融合和病毒感染性测定中进行了评估。我们发现(a)活性仅基于增加的疏水性含量稳定在约200 nM;(b)双吲哚支架的功效超过其他杂环系统;(c)可能在口袋中涉及Gln575的极性相互作用可以取代特异性较低的疏水相互作用;(d)苯甲酸酯部分似乎没有与袋形成特定的接触。该疏水基团对化合物效价的重要性表明了一种机制,在融合过程中它可能与第三组分(例如膜)相互作用。与较早的化合物相比,发现了一种有前途
    DOI:
    10.1016/j.ejmech.2018.10.048
  • 作为产物:
    描述:
    碘甲烷 在 sodium hydride 作用下, 以 四氢呋喃 为溶剂, 反应 0.5h, 以51%的产率得到6-溴-1-甲基吲唑
    参考文献:
    名称:
    WO2007/84451
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • COMPOUNDS AND USES THEREOF
    申请人:Yumanity Therapeutics, Inc.
    公开号:US20190330198A1
    公开(公告)日:2019-10-31
    The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    本发明涉及用于治疗神经系统疾病的化合物。本发明的化合物可以单独或与其他药用活性剂结合使用,用于治疗或预防神经系统疾病。
  • [EN] N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE UTILES EN TANT QU'INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE
    申请人:BIOMARIN PHARM INC
    公开号:WO2015065937A1
    公开(公告)日:2015-05-07
    Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    本处描述的是公式I的化合物,制造此类化合物的方法,包含此类化合物的药物组合物和药品,以及用于治疗或预防与葡萄糖苷鞘氨醇合酶(GCS)相关疾病的I化合物。
  • Oxalic Diamides and <i>tert</i>-Butoxide: Two Types of Ligands Enabling Practical Access to Alkyl Aryl Ethers via Cu-Catalyzed Coupling Reaction
    作者:Zhixiang Chen、Yongwen Jiang、Li Zhang、Yinlong Guo、Dawei Ma
    DOI:10.1021/jacs.8b12142
    日期:2019.2.27
    A robust and practical protocol for preparing alkyl aryl ethers has been developed, which relies on using two types of ligands to promote Cu-catalyzed alkoxylation of (hetero)aryl halides. The reaction scope is very general for a variety of coupling partners, particularly for challenging secondary alcohols and (hetero)aryl chlorides. In case of coupling with aryl chlorides and bromides, two oxalic
    已经开发了一种用于制备烷基芳基醚的稳健实用的方案,该方案依赖于使用两种类型的配体来促进 Cu 催化的(杂)芳基卤化物的烷氧基化。反应范围非常适用于各种偶联伙伴,尤其是具有挑战性的仲醇和(杂)芳基氯。在与芳基氯化物和溴化物偶联的情况下,两个草酸二酰胺作为强大的配体。叔丁醇首先被证明是铜催化偶联反应的配体,导致芳基碘化物在室温下完成烷氧基化。此外,许多碳水化合物衍生物适用于该偶联反应,以 29-98% 的产率提供相应的碳水化合物-芳基醚。
  • 小分子PD-1/PD-L1抑制剂、其与PD-L1抗体的药物组合物及其应用
    申请人:上海再极医药科技有限公司
    公开号:CN111714628A
    公开(公告)日:2020-09-29
    本发明公开了一种小分子PD‑1/PD‑L1抑制剂、其与PD‑L1抗体的药物组合物及其应用。其中,该小分子PD‑1/PD‑L1抑制剂例如通式(I)所示的芳香乙烯或芳香乙基类衍生物,其可以用于治疗癌症。
  • HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    申请人:Chytil Milan
    公开号:US20100204214A1
    公开(公告)日:2010-08-12
    Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    本文提供了融合咪唑基化合物,其合成方法以及使用方法。本文提供的化合物对于治疗、预防和/或管理各种疾病,如神经系统疾病和代谢性疾病,具有用处。本文提供的化合物抑制组胺H3受体的活性,并调节各种神经递质的释放,如组胺、乙酰胆碱、去甲肾上腺素和多巴胺(例如在突触处)。本文还提供了含有这些化合物的药物配方及其使用方法。
查看更多